Table 1.
EGFR aberrations and cancer: overview.
| Disease | No of patients with EGFR mutation total (%) | EGFR mutation information | Comment | Reference |
|---|---|---|---|---|
| Ovarian Cancer | 1/25 (4%) | Exon 19 deletion | Patient with mutation was only one to achieve a partial remission on the EGFR inhibitor gefitinib | (Schilder et al., 2005) |
| Squamous cell cancer of the head and neck | 3/41 (7.3%) | Deletion in Exon 19 | (Lee et al., 2005) | |
| Cholangiocarcinoma | 3/22 (13.6%) | Deletion in Exon 19 | (Gwak et al., 2005) | |
| Prostate Cancer | 4/89 (4.5%) | Missense mutations in exons 19, 20 and 21 | (Douglas et al., 2006) | |
| Colorectal cancer | 4/33 (12%) | Mutations in exons 19 (codon 749) or exon 20 (codons 762 and 767) | (Nagahara et al., 2005) | |
| Esophageal | 2/17 (11.7%) | Exon 19 deletion and exon 21 L858R mutation | (Kwak et al., 2006) | |
| Barrett's esophagus | 3/21 (14.2%) | Deletion in exon 19 (N = 2) and exon 20 mutation in T790 M | T790 M is drug resistant | (Kwak et al., 2006) |
| Pancreatic cancer | 2/55 (3.6%) | Deletion in exon 19 | Disease stabilization with erlotinib and capecitabine | (Kwak et al., 2006) |
| Non‐small cell lung cancer | 68/278 (24%) | Most commonly exon 19 deletions, exon 21 point mutation L858R | Associated with no prior smoking, prolonged survival and response to EGFR inhibitors | (Sequist et al., 2007) |
| Non‐small cell lung cancer | 38/98 (38.8%) | Most commonly exon 19 deletions, exon 21 point mutaion L858R | Japanese population.Associated with no prior smoking, prolonged survival and response to EGFR inhibitors | (Ichihara et al., 2007) |